Ace Therapeutics, a specialized contract research organization (CRO) focused on translational blood disorder research, has announced the launch of its full-scale preclinical hematology CRO services. The comprehensive suite integrates in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics under a unified scientific framework. The announcement underscores efforts to address bottlenecks in translational research for hematologic diseases, which include inherited anemias, autoimmune conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders.
Traditional preclinical research often faces limitations in model translatability and end-to-end study execution. Ace Therapeutics' preclinical hematology CRO services aim to overcome these challenges by offering a robust collection of in vivo hematologic disease models built across multiple species, including mice, rats, dogs, and non-human primates. The model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft (PDX) constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, the CRO's services deliver cutting-edge in vitro modeling platforms, including biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays utilizing primary human CD34+ hematopoietic stem and progenitor cells sourced from bone marrow, cord blood, and mobilized peripheral blood. These tools enable high-throughput, human-relevant mechanistic research.
Beyond model development, the services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling. Hematology-focused safety pharmacology and toxicology assessments evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues including the spleen and bone marrow. Specialized technical support is offered for all therapeutic modalities, ranging from small-molecule iron chelators and JAK inhibitors to monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients can collaborate with Ace Therapeutics to design tailored study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions.
